Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9008733 | 0.82 | TACR2 (0.83) | TACR2TACR1 | |
| SCHEMBL5013628 | 0.82 | TACR2 (0.69) | TACR2TACR1 | |
| SCHEMBL5810226 | 0.82 | TACR2 (0.69) | TACR2TACR1 | |
| Acetic Acid SCHEMBL4256160 | 0.82 | TACR2 (0.69) | TACR2TACR1 | |
| SCHEMBL8292511 | 0.82 | TACR2 (0.84) | TACR2TACR1 | |
| SCHEMBL4609838 | 0.82 | TACR2 (0.69) | TACR2TACR1 | |
| SCHEMBL759334 | 0.82 | TACR2 (0.82) | TACR2TACR1 | |
| SCHEMBL6170809 | 0.82 | TACR2 (0.82) | TACR2TACR1 | |
| SCHEMBL4265273 | 0.81 | TACR2 (0.68) | TACR2 | |
| SCHEMBL7681036 | 0.81 | TACR2 (0.73) | TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940845-B1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ALBIREO AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8288370-B2 | Substituted azetidine compounds of formula (I) useful in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia | ALBIREO AB (SE) | 2012-10-16 | — | — | US | disclosed |
| US-8106208-B2 | Benzamide compounds that act as NK receptor antagonists | ALBIREO AB (SE) | 2012-01-31 | — | — | US | disclosed |
| EP-2024354-B1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2011-09-21 | — | — | EP | disclosed |
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| US-20100069346-A1 | New Azetidine Derivatives as Neurokinin Receptor Antagonists for the Treatment of Gastrointestinal Diseases | ALBIREO AB (SE) | 2010-03-18 | — | — | US | disclosed |
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| EP-2024354-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | Albireo AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| WO-2008076041-A1 | AZETIDINAZABICYCLO [3.2.1] OCTAN DERIVATIVES THAT ARE NEUROKININ (NK) RECEPTOR ANTAGONISTS AND THEIR USE. | ALBIREO AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146538-A1 | Compounds 614 | ALBIREO AB (SE) | 2008-06-19 | — | — | US | disclosed |
| WO-2007136325-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 2 | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136324-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270400-A1 | New compounds 303 | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270399-A1 | New compounds 302 | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20060172988-A1 | Azetidine compounds | ALBIREO AB (SE) | 2006-08-03 | — | — | US | disclosed |
| EP-1636221-A2 | NEW AZETIDINE COMPOUNDS | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110344-A2 | NEW AZETIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | NISCH, BDKRB2, VIP | TACR2 8/4885TACR1 6/4885 |
| US-20100069346-A1 | New Azetidine Derivatives as Neurokinin Receptor Antagonists for the Treatment of Gastrointestinal Diseases | GIPR, HRH2, BDKRB2 | TACR2 5/4885TACR1 8/4885 |
| US-20070270400-A1 | New compounds 303 | CYP11B2, CYP11B1, SDHA | TACR2 80/4885TACR1 155/4885 |
| US-20080146538-A1 | Compounds 614 | CYP4A11, CYP4B1, CYP11B2 | TACR2 169/4885TACR1 149/4885 |
| US-20070270398-A1 | New Compounds III | CYP11B2, CYP11B1, SDHA | TACR2 110/4885TACR1 154/4885 |
| US-20070270399-A1 | New compounds 302 | CYP11B2, CYP11B1, CYP4B1 | TACR2 54/4885TACR1 106/4885 |
| US-20060172988-A1 | Azetidine compounds | HRH2, HRH4, HRH1 | TACR2 19/4885TACR1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.